Zulvac 1 Ovis

RSS

Withdrawn

This medicine's authorisation has been withdrawn

inactivated bluetongue virus, serotype-1
MedicineVeterinaryWithdrawn

Czech is available via eTranslation, the European Commission's machine translation service.

Translate to Czech | Important information about machine translation

  • Application under evaluation
  • CVMP opinion
  • European Commission decision

Overview

The marketing authorisation for Zulvac 1 Ovis has been withdrawn at the request of the marketing-authorisation holder.

български (BG) (387.71 KB - PDF)

Zobrazit

español (ES) (324.29 KB - PDF)

Zobrazit

čeština (CS) (367.61 KB - PDF)

Zobrazit

dansk (DA) (311.6 KB - PDF)

Zobrazit

Deutsch (DE) (339.3 KB - PDF)

Zobrazit

ελληνικά (EL) (425.96 KB - PDF)

Zobrazit

français (FR) (340.13 KB - PDF)

Zobrazit

italiano (IT) (335.8 KB - PDF)

Zobrazit

latviešu (LV) (411.71 KB - PDF)

Zobrazit

lietuvių (LT) (350.56 KB - PDF)

Zobrazit

magyar (HU) (383.87 KB - PDF)

Zobrazit

Malti (MT) (373.83 KB - PDF)

Zobrazit

Nederlands (NL) (320.6 KB - PDF)

Zobrazit

polski (PL) (381.01 KB - PDF)

Zobrazit

português (PT) (329.18 KB - PDF)

Zobrazit

română (RO) (327.6 KB - PDF)

Zobrazit

slovenčina (SK) (357.21 KB - PDF)

Zobrazit

slovenščina (SL) (375.83 KB - PDF)

Zobrazit

suomi (FI) (335.83 KB - PDF)

Zobrazit

svenska (SV) (303.24 KB - PDF)

Zobrazit

Product information

български (BG) (747.04 KB - PDF)

Zobrazit

español (ES) (415.86 KB - PDF)

Zobrazit

čeština (CS) (625.49 KB - PDF)

Zobrazit

dansk (DA) (420.56 KB - PDF)

Zobrazit

Deutsch (DE) (442.48 KB - PDF)

Zobrazit

eesti (ET) (426.62 KB - PDF)

Zobrazit

ελληνικά (EL) (744.06 KB - PDF)

Zobrazit

français (FR) (441.63 KB - PDF)

Zobrazit

hrvatski (HR) (487.06 KB - PDF)

Zobrazit

italiano (IT) (439.98 KB - PDF)

Zobrazit

latviešu (LV) (612.09 KB - PDF)

Zobrazit

lietuvių (LT) (492.04 KB - PDF)

Zobrazit

magyar (HU) (645.11 KB - PDF)

Zobrazit

Malti (MT) (643.64 KB - PDF)

Zobrazit

Nederlands (NL) (428.46 KB - PDF)

Zobrazit

polski (PL) (637.5 KB - PDF)

Zobrazit

português (PT) (424.02 KB - PDF)

Zobrazit

română (RO) (523 KB - PDF)

Zobrazit

slovenčina (SK) (629.98 KB - PDF)

Zobrazit

slovenščina (SL) (619.27 KB - PDF)

Zobrazit

suomi (FI) (412.23 KB - PDF)

Zobrazit

svenska (SV) (434.1 KB - PDF)

Zobrazit

Íslenska (IS) (431.83 KB - PDF)

Zobrazit

norsk (NO) (426.93 KB - PDF)

Zobrazit
Latest procedure affecting product information:IB/00017
21/06/2019

български (BG) (853.9 KB - PDF)

Zobrazit

español (ES) (837.98 KB - PDF)

Zobrazit

čeština (CS) (862.38 KB - PDF)

Zobrazit

dansk (DA) (806.02 KB - PDF)

Zobrazit

Deutsch (DE) (827.27 KB - PDF)

Zobrazit

eesti (ET) (805.45 KB - PDF)

Zobrazit

ελληνικά (EL) (877.4 KB - PDF)

Zobrazit

français (FR) (824.01 KB - PDF)

Zobrazit

italiano (IT) (801.5 KB - PDF)

Zobrazit

latviešu (LV) (843.42 KB - PDF)

Zobrazit

lietuvių (LT) (1.38 MB - PDF)

Zobrazit

magyar (HU) (853.89 KB - PDF)

Zobrazit

Malti (MT) (847.1 KB - PDF)

Zobrazit

Nederlands (NL) (824.2 KB - PDF)

Zobrazit

polski (PL) (862.36 KB - PDF)

Zobrazit

português (PT) (837.86 KB - PDF)

Zobrazit

română (RO) (1.38 MB - PDF)

Zobrazit

slovenčina (SK) (839.69 KB - PDF)

Zobrazit

slovenščina (SL) (858.77 KB - PDF)

Zobrazit

suomi (FI) (824.89 KB - PDF)

Zobrazit

svenska (SV) (805.81 KB - PDF)

Zobrazit

Íslenska (IS) (806.86 KB - PDF)

Zobrazit

norsk (NO) (804.7 KB - PDF)

Zobrazit

Product details

Name of medicine
Zulvac 1 Ovis
Active substance
inactivated bluetongue virus, serotype-1
International non-proprietary name (INN) or common name
inactivated bluetongue virus, serotype-1
Species
Sheep
Anatomical therapeutic chemical veterinary (ATCvet) code
QI04AA02

Pharmacotherapeutic group

Immunologicals

Therapeutic indication

Active immunisation of sheep from 1.5 months of age for the prevention of viraemia caused by bluetongue virus, serotypes-1.

Onset of immunity: 21 days after completion of the primary vaccination scheme.

Duration of immunity: 12 months.

Authorisation details

EMA product number
EMEA/V/C/002335

Accelerated assessment

This medicine had an accelerated assessment. This means that it is a medicine of major interest for public health, so its timeframe for review was 150 evaluation days rather than 210. For more information, see Accelerated assessment.

Marketing authorisation holder
Zoetis Belgium SA

Rue Laid Burniat 1
1348 Louvain-la-Neuve
Belgium

Marketing authorisation issued
05/08/2011
Revision
6

Assessment history

This page was last updated on

Share this page